PMID- 23819335
OWN - NLM
STAT- MEDLINE
DCOM- 20130722
LR  - 20161125
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 85
IP  - 5
DP  - 2013
TI  - [Relationship of the clinical efficiency of tocilizumab therapy to the serum 
      level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
PG  - 24-9
AB  - AIM: To evaluate the impact of tocilizumab (TCZ) therapy on the level of matrix 
      metalloproteinase-3 (MMP-3) 4, 24, and 48 weeks after treatment initiation in 
      relation to the clinical efficiency of TCZ therapy by the Disease Activity Score 
      (DAS28), the Clinical Disease Activity Index (CDAI), and the Simplified Disease 
      Activity Index (SDAI). SUBJECTS AND METHODS: Forty-two rheumatoid arthritis (RA) 
      patients who had received 6 intravenous infusions of TCZ 8 mg/kg at a 4-week 
      interval during permanent therapy with disease-modifying anti-rheumatic drugs 
      (DMARD) and glucocorticosteroids (GCS) were examined. Then TCZ was discontinued 
      and the patients continued to receive the previous therapy with DMARD and GCS. 
      The European League Against Rheumatism (EULAR) classification criteria, as well 
      as SDAI and CDAI were used to evaluate the efficiency of TCZ therapy. The serum 
      concentration of MMP-3 was measured by enzyme immunoassay using the test systems 
      (Invitrogen, USA). RESULTS: After 24 weeks of TCZ therapy (at 48 weeks following 
      trial initiation), DAS28 was 4.69 (3.86; 5.44); the SDAI of 17.8 (10.7; 29.5) and 
      the CDAI of 17.1 (7.2; 26.2) corresponded to moderate disease activity. At 48 
      weeks, DAS28 remission (< 2.6 scores) remained in 5 (11.90%) patients; SDAI (< or 
      = 3.3 scores) and CDAI (< or = 2.8 scores) remissions did in 3 (7.1%) and 4 
      (9.5%) patients, respectively. There was a significant reduction in MMP-3 
      concentrations at 4, 24, and 48 weeks of the therapy, which was 61, 73, and 
      49.40% of the baseline level. ROC analysis indicated that the normalization of 
      MMP-3 levels in RA patients at 24 weeks of TCZ therapy (a cut-off < or =16.5 
      ng/ml) was associated with the maintenance of remission/low disease activity from 
      SDAI and CDAI 24 weeks after the drug use (the area under the receiver operating 
      curve was 0.762; 95% confidence interval: 0.548-0.976). CONCLUSION: Analysis of 
      the results of 48-week TCZ therapy suggests its ability to reduce the levels of 
      markers of bone and cartilage destruction in patients with RA. Serum MMP-3 
      determination at 24 weeks of therapy may be useful in predicting the maintenance 
      of remission/low activity from SDAI and CDAI after discontinuation of the drug.
FAU - Avdeeva, A S
AU  - Avdeeva AS
FAU - Aleksandrova, E N
AU  - Aleksandrova EN
FAU - Novikov, A A
AU  - Novikov AA
FAU - Cherkasova, M V
AU  - Cherkasova MV
FAU - Panasyuk, E Yu
AU  - Panasyuk EY
FAU - Nasonov, E L
AU  - Nasonov EL
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Glucocorticoids)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use
MH  - Antirheumatic Agents/administration & dosage/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Bone and Bones/pathology
MH  - Cartilage/pathology
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Infusions, Intravenous
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - ROC Curve
MH  - Remission Induction
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2013/07/04 06:00
MHDA- 2013/07/23 06:00
CRDT- 2013/07/04 06:00
PHST- 2013/07/04 06:00 [entrez]
PHST- 2013/07/04 06:00 [pubmed]
PHST- 2013/07/23 06:00 [medline]
PST - ppublish
SO  - Ter Arkh. 2013;85(5):24-9.